Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. However, there was a similar incidence of allergic reactions associated with other non-depolarizing neuromuscular blocking agents. Sugammadex is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.
For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
CHU Necker, Paris, France
CHU de La Réunion, Saint Denis, La Réunion, France
CHU de la Réunion, Saint Pierre, La Réunion, France
Dr. Horst Schmidt Klinik, Wiesbaden, Hessen, Germany
Antwerp University Hospital, Edegem, Antwerpen, Belgium
General University Hospital in Prague, Prague, Czechia
Herzzentrum Leipzig GmbH, Leipzig, Germany
Department of minimal invasive gynecology Aleris-Hamlet Private Hospital, Copenhagen, Søborg, Denmark
Azsintjan, Brugge, Belgium
Dr. Horst Schmidt Kliniken, Wiesbaden, Germany
Chosun University Hospital, Gwangju, Korea, Republic of
KKH Dormagen, Dormagen, Germany
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.